We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

(Reuters) -Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico in 2025, Chief Financial Officer Lucas Montarce said on Monday at the ...

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs Zepbound and Mounjaro. In a sealed decision ...

Just last week, Eli Lilly announced it is expanding the supply and cutting the costs of its weight-loss drug Zepbound, again, effectively broadening access to more patients without insurance with ...

Novo Nordisk A/S (NVO) has slashed prices for its blockbuster weight-loss drug Wegovy as competition in the obesity drug market heats up, with Eli Lilly (LLY) as a key rival. The company launched ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 25 trades. If we consider the specifics of ...

Eli Lilly has launched new 7.5 mg and 10 mg single-dose vials of Zepbound (tirzepatide), priced at $499 per month under the newly introduced Zepbound Self Pay Journey Program. The company said ...

Leading the charge is Eli Lilly, which last week announced a $27 billion investment in four different domestic manufacturing plants designed to help meet the rabid demand for its catalog of ...

Credit: shisu_ka/Shutterstock. Magnet Biomedicine has entered a partnership and licence agreement with Eli Lilly to discover, develop and commercialise oncology molecular glue therapeutics. The ...

Eli Lilly is set to keep growing its revenue at a strong pace in the next five years. The company is likely to add important medicines to its lineup. Eli Lilly's shares look attractive right now.